Fluorescence PCR Test Spots Macrolide-Resistant Mycoplasma pneumoniae in Hours

Macrolide antibiotics such as azithromycin have long been the cornerstone of treatment for Mycoplasma pneumoniae, a leading cause of community-acquired pneumonia, particularly in children and young adults. Yet across much of Asia and increasingly elsewhere, strains of this atypical bacterium have acquired mutations that render macrolides nearly useless, forcing clinicians to fall back on second-line drugs that are not always suitable for pediatric patients. A team of researchers at Samsung Medical Center in Seoul has now developed a rapid fluorescence-based genotyping assay that can identify the two most clinically important resistance mutations directly from respiratory specimens, potentially giving physicians the molecular evidence they need to choose the right antibiotic within hours rather than days. The work, published in Applied Microbiology and Biotechnology, describes a minor groove binding (MGB) probe-based polymerase chain reaction (PCR) assay designed to discriminate between point mutations at positions 2063 and 2064 of the bacterial 23S ribosomal RNA gene.

The biological target of the new assay is domain V of the 23S rRNA gene, the region of the bacterial ribosome where macrolides normally bind to halt protein synthesis. Point mutations at nucleotide positions 2063 and 2064, most commonly the substitutions A2063G and A2064G, alter the architecture of the macrolide binding pocket so that the drug can no longer attach effectively. These two adjacent sites account for the overwhelming majority of macrolide-resistant M. pneumoniae infections worldwide, and distinguishing between them matters because the prevalence and clinical behavior of each genotype can differ by geography and outbreak context. Conventional detection relies on Sanger sequencing of amplified DNA, a reliable but slow and labor-intensive process that requires expensive equipment, multiple handling steps, and expert interpretation. Real-time PCR approaches exist, but many depend on melting-curve analysis, which can be technically demanding when the mutations of interest sit only a single nucleotide apart.

The Korean team, led by Hyeonseek Park and Minhee Kang of the Biomedical Engineering Research Center at Samsung Medical Center’s Smart Healthcare Research Institute, together with Sun Ae Yun, Tae Yeul Kim, and Hee Jae Huh, tackled this discrimination problem with minor groove binding probes. MGB probes are short DNA oligonucleotides conjugated to a small molecule that wedges into the minor groove of the DNA double helix, dramatically stabilizing the probe-target duplex. This added stabilization permits the use of very short probes, and short probes are exquisitely sensitive to even a single mismatched base. By designing position-specific MGB probes that selectively bind the mutant sequences at positions 2063 and 2064, the researchers created a multiplex assay in which each genotype lights up with its own fluorescence signature, allowing accurate discrimination of point mutations at the two adjacent nucleotide sites within the same reaction tube.

Achieving clean separation between genotype-specific fluorescence signals required careful optimization of the reaction conditions. One of the key findings reported by the team was that decreasing primer concentrations improved probe-target discrimination, a counterintuitive adjustment that reduces the amplification pressure favoring imperfect probe binding and sharpens the boundary between true signal and background. With the optimized chemistry, the assay assigns genotypes purely from endpoint fluorescence readings, eliminating the need for melting-curve analysis altogether. That simplification matters operationally: endpoint genotyping reduces the analytical complexity of the run, shortens the time to result, and makes the workflow easier to implement on standard real-time PCR instruments already present in clinical laboratories, without requiring specialized high-resolution melting hardware or bespoke analysis software.

Analytical performance figures reported in the study are striking. The limits of detection were 31.0 copies per milliliter for the wild-type genotype, 27.2 copies per milliliter for A2063G, 43.2 copies per milliliter for A2063C, 39.3 copies per milliliter for A2063T, and 32.7 copies per milliliter for A2064G. These values, all in the low tens of copies per milliliter, indicate that the assay can detect resistance mutations even when the bacterial load in a respiratory specimen is very low, a situation common in later stages of infection or after partial antibiotic treatment. Notably, the assay covers not only the two dominant mutations but also the rarer A2063C and A2063T substitutions, giving it a broader genotypic reach than many existing rapid tests that focus on a single variant.

Specificity is as critical as sensitivity in a genotyping assay intended for clinical decision-making, because a false resistance call could push a clinician toward unnecessary second-line therapy. The researchers evaluated cross-reactivity against a panel of 24 non-target respiratory pathogens, including the bacteria and viruses most likely to co-circulate with M. pneumoniae in patients with pneumonia, and observed no cross-reactivity among any of them. This clean specificity profile reflects the design logic of the MGB probes: because each probe is short and stabilized by the minor groove binder, only a perfect match to the target sequence produces a stable fluorescent signal, while sequences from other organisms or the wild-type allele dissociate and remain dark.

The clinical evaluation used 44 respiratory specimens obtained from 44 patients with suspected M. pneumoniae infection, analyzed under a protocol approved by the Samsung Medical Center Institutional Review Board with the informed consent requirement waived because the study was retrospective and used de-identified leftover specimens. Sanger sequencing, the traditional reference standard, yielded interpretable results for 40 of the 44 specimens, and the new MGB probe-based assay was fully concordant with the sequence-based reference results in all 40 cases. The four specimens that sequencing could not resolve underscore a practical advantage of the rapid assay: low bacterial loads that defeat conventional sequencing can still fall within the detection range of a sensitive probe-based PCR, meaning the genotyping result may be available precisely when sequencing fails.

Against a commercially available real-time PCR assay, the developed method achieved 100 percent overall percent agreement across all 44 specimens, with a 95 percent confidence interval of 92.0 to 100.0 percent and a Cohen’s kappa of 1.00, the statistical ceiling for perfect agreement. While the sample size is modest and larger multi-center validations will be needed before widespread adoption, the combination of perfect concordance with both a sequencing reference and an established commercial assay provides strong initial evidence that the endpoint genotyping approach performs reliably on real clinical material. The study was supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare of the Republic of Korea, and by the Future Medicine 2030 Project of the Samsung Medical Center, and the authors declared no competing interests.

The clinical significance of rapid macrolide resistance genotyping is difficult to overstate in regions where resistant strains dominate. In parts of East Asia, the majority of circulating M. pneumoniae isolates carry A2063G or A2064G, meaning that empiric macrolide therapy frequently fails, prolonging fever, extending hospital stays, and increasing transmission. When a laboratory can report within a single working day that a patient’s isolate carries a resistance mutation, physicians can switch promptly to alternatives such as tetracyclines or fluoroquinolones, the latter reserved for older patients because of effects on cartilage development. The authors conclude that the multiplex MGB probe-based PCR assay allows rapid and reliable detection of closely spaced macrolide resistance mutations in M. pneumoniae and could support timely antimicrobial decision-making in clinical settings, a framing that positions the test as a practical stewardship tool rather than a purely research instrument.

More broadly, the study illustrates how probe chemistry refinements can solve a persistent molecular diagnostics challenge: distinguishing mutations that sit immediately adjacent to one another in a short stretch of DNA. Minor groove binding technology has found applications across oncology, virology, and microbiology, but the demonstration that endpoint fluorescence alone, without melting analysis, can resolve two neighboring nucleotide positions in a clinically relevant pathogen offers a template for other resistance genotyping assays, from tuberculosis drug resistance to antiviral mutations. As macrolide-resistant M. pneumoniae continues its geographic spread, tools of this kind, fast, sensitive to a few dozen genome copies, and deployable on existing laboratory instruments, may become an essential part of the diagnostic arsenal that keeps antibiotic choices targeted, effective, and sustainable.

Subject of Research: Rapid endpoint genotyping of macrolide resistance mutations in Mycoplasma pneumoniae using minor groove binding probe PCR

Article Title: Endpoint genotyping of A2063G and A2064G mutations in Mycoplasma pneumoniae

Article References: Park, H., Kang, M., Yun, S. A., Kim, T. Y., & Huh, H. J. (2026). Endpoint genotyping of A2063G and A2064G mutations in Mycoplasma pneumoniae. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14041-3

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14041-3

Keywords: Mycoplasma pneumoniae, macrolide resistance, 23S rRNA, A2063G, A2064G, minor groove binder probe, endpoint genotyping, PCR, antimicrobial resistance, diagnostics, respiratory infection, molecular assay